Lecture image placeholder

Premium content

Access to this content requires a subscription. You must be a premium user to view this content.

Monthly subscription - $9.99Pay per view - $4.99Access through your institutionLogin with Underline account
Need help?
Contact us
Lecture placeholder background
VIDEO DOI: https://doi.org/10.48448/s060-nd69

technical paper

ENDO 2020

June 10, 2020

Virtual, United States

Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss

Please log in to leave a comment

Downloads

Transcript English (automatic)

Next from ENDO 2020

Resiliency and Managing Burnout
technical paper

Resiliency and Managing Burnout

ENDO 2020

Deborah T. Rana
Deborah T. Rana

10 June 2020

Similar lecture

Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome
technical paper

Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome

ENDO 2020

+7Paul D. MillerTricia CimmsThomas O. Carpenter
Thomas O. Carpenter and 9 other authors

10 June 2020

Stay up to date with the latest Underline news!

Select topic of interest (you can select more than one)

PRESENTATIONS

  • All Lectures
  • For Librarians
  • Resource Center
  • Free Trial
Underline Science, Inc.
1216 Broadway, 2nd Floor, New York, NY 10001, USA

© 2023 Underline - All rights reserved